Recent Updates
Recently added Catalysts

EPI-589

Phase 2

Amyotrophic Lateral Sclerosis | Small molecule | Neurology |PTC Therapeutics, Inc.|Last Updated: Oct 14, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment19
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02460679Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)PHASE2 COMPLETED 19Jan 14, 2016Feb 23, 2018Oct 14, 20203 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Drug-Related Serious Adverse Events (SAEs)
Baseline (Day 0) to Month 6

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Secondary Endpoints
Area Under the Plasma Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12)
Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose at Month 1 and 3
Maximum Observed Plasma Concentration (Cmax)
Pre-dose (0 hour), 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose at Month 1 and 3
Change From Baseline in ALSFRS-R Total Score at Month 6
Baseline, Month 6
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EPI-589EXPERIMENTALParticipants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
Interventions
NameTypeDescription
EPI-589DRUGAn immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Diagnosis of possible, probable, laboratory supported probable, or definite ALS by E1 Escorial Criteria * Forced vital capacity (FVC) ≥ 70% of predicted * Weakness onset within 3 years * Agreement to use contraception if within reproductive years * Willingness and ability to c...

Countries:United States
Unlock Eligibility Criteria